MCID: SKN022
MIFTS: 50

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Skin 12 73
Epidermoid Skin Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3151
NCIt 50 C4819
SNOMED-CT 68 254651007
UMLS 73 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to squamous cell carcinoma and palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal. An important gene associated with Skin Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Cytokine Signaling in Immune system. The drugs Fluorouracil and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Skin Squamous Cell Carcinoma

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.5 BRAF CDKN2A HRAS KRAS PIK3CA TP53
2 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.5
3 pseudovascular skin squamous cell carcinoma 12.1
4 epidermodysplasia verruciformis 11.3
5 anal margin squamous cell carcinoma 11.1
6 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
7 nevus of ota 10.8 BRAF TP53
8 keratinizing squamous cell carcinoma 10.8 CDKN2A TP53
9 gallbladder adenoma 10.8 CDKN2A HRAS
10 adult hepatocellular carcinoma 10.8 PIK3CA TP53
11 melanomatosis 10.8 CDKN2A HRAS
12 malignant spiradenoma 10.8 PIK3CA TP53
13 bladder carcinoma in situ 10.7 CDKN2A TP53
14 lip cancer 10.7 BRAF TP53
15 bartholin's gland benign neoplasm 10.7 CDKN2A TP53
16 sigmoid neoplasm 10.7 HRAS KRAS
17 vulva squamous cell carcinoma 10.7 CDKN2A TP53
18 thyroid lymphoma 10.6 CDKN2A TP53
19 schimmelpenning-feuerstein-mims syndrome 10.6 HRAS KRAS
20 penile cancer 10.6 CDKN2A HRAS TP53
21 periampullary adenoma 10.6 HRAS KRAS
22 paronychia 10.6 HRAS KRAS
23 integumentary system cancer 10.6 CDKN2A HRAS TP53
24 melanoma, cutaneous malignant 1 10.6 CDKN2A HRAS TP53
25 bile duct cysts 10.6 HRAS KRAS
26 mutyh-associated polyposis 10.6 KRAS TP53
27 transitional cell carcinoma 10.6 CDKN2A HRAS TP53
28 ethmoid sinus cancer 10.6 HRAS PIK3CA
29 anal squamous cell carcinoma 10.6 CDKN2A PIK3CA TP53
30 prostate adenoid cystic carcinoma 10.5 HRAS LRRC56 PIK3CA
31 ethmoid sinus adenocarcinoma 10.5 HRAS PIK3CA
32 syringocystadenoma papilliferum 10.5 BRAF KRAS
33 epithelial-myoepithelial carcinoma 10.5 FBXW7 HRAS TP53
34 adenoid basal cell carcinoma 10.5 B2M CDKN2A
35 brain stem glioma 10.5 BRAF PIK3CA TP53
36 biliary papillomatosis 10.5 HRAS KRAS TP53
37 mixed cell type cancer 10.5 HRAS KRAS TP53
38 barrett's adenocarcinoma 10.5 CDKN2A KRAS TP53
39 ovary adenocarcinoma 10.5 HRAS KRAS TP53
40 liver angiosarcoma 10.4 HRAS KRAS TP53
41 bile duct adenocarcinoma 10.4 HRAS KRAS TP53
42 anaplastic thyroid cancer 10.4 BRAF PIK3CA TP53
43 acral lentiginous melanoma 10.4 BRAF CDKN2A
44 intestinal benign neoplasm 10.4 HRAS KRAS TP53
45 hyperplastic polyposis syndrome 10.4 BRAF KRAS TP53
46 lung benign neoplasm 10.4 HRAS KRAS TP53
47 endometrial adenocarcinoma 10.4 CDKN2A KRAS TP53
48 spinal cancer 10.4 FAT2 TP53
49 mature teratoma 10.4 BRAF KRAS TP53
50 bladder adenocarcinoma 10.4 FBXW7 HRAS

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10 KRAS PIK3CA BRAF HRAS
2 Decreased viability GR00106-A-0 10 KRAS
3 Decreased viability GR00221-A-1 10 HRAS KRAS PIK3CA
4 Decreased viability GR00221-A-2 10 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10 HRAS
6 Decreased viability GR00221-A-4 10 PIK3CA BRAF
7 Decreased viability GR00301-A 10 KRAS BRAF
8 Decreased viability GR00381-A-1 10 KRAS BRAF
9 Decreased viability GR00402-S-2 10 HRAS KRAS PIK3CA BRAF
10 Decreased cell migration GR00055-A-1 9.55 HRAS KRAS PIK3CA RAC1 BRAF
11 Increased cell migration GR00055-A-3 9.02 KRAS PIK3CA BRAF RAC1 HRAS

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.27 RAC1 PIK3CA TP53 CDKN2A BRAF B2M
2 cellular MP:0005384 10.27 TP53 RAC1 PIK3CA B2M CD151 CDKN2A
3 growth/size/body region MP:0005378 10.25 TP53 RAC1 PIK3CA CDKN2A BRAF B2M
4 endocrine/exocrine gland MP:0005379 10.22 RAC1 PIK3CA TP53 CDKN2A BRAF B2M
5 homeostasis/metabolism MP:0005376 10.22 PIK3CA TP53 RAC1 B2M CD151 CDKN2A
6 immune system MP:0005387 10.2 RAC1 STAT2 PIK3CA TP53 CDKN2A BRAF
7 hematopoietic system MP:0005397 10.19 TP53 RAC1 STAT2 CD151 CDKN2A BRAF
8 integument MP:0010771 10.17 RAC1 PIK3CA TP53 CDKN2A BRAF B2M
9 digestive/alimentary MP:0005381 10.15 TP53 CDKN2A BRAF B2M KRAS HRAS
10 mortality/aging MP:0010768 10.15 TP53 RAC1 STAT2 PIK3CA CDKN2A BRAF
11 craniofacial MP:0005382 10.1 TP53 RAC1 BRAF FBXW7 KRAS HRAS
12 embryo MP:0005380 10.08 PIK3CA TP53 RAC1 KRAS CDKN2A BRAF
13 neoplasm MP:0002006 10.02 PIK3CA TP53 CDKN2A BRAF B2M CD151
14 nervous system MP:0003631 9.91 PIK3CA TP53 RAC1 KRAS B2M BRAF
15 liver/biliary system MP:0005370 9.88 TP53 KRAS B2M BRAF FBXW7 CDKN2A
16 reproductive system MP:0005389 9.56 PIK3CA TP53 RAC1 B2M CDKN2A BRAF
17 pigmentation MP:0001186 9.55 TP53 RAC1 CDKN2A BRAF KRAS
18 vision/eye MP:0005391 9.17 PIK3CA TP53 CDKN2A BRAF KLF4 FBXW7

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 2 51-21-8 3385
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
3
Acitretin Approved Phase 4,Phase 2,Not Applicable 55079-83-9 6437841 5284513
4 Antimetabolites Phase 4,Phase 3,Phase 2
5 Antimetabolites, Antineoplastic Phase 4,Phase 2
6 Dermatologic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
8 Tin Fluorides Phase 4
9 triamcinolone acetonide Phase 4,Phase 2
10 Triamcinolone diacetate Phase 4,Phase 2
11 Triamcinolone hexacetonide Phase 4,Phase 2
12 Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Hormones Phase 4,Phase 3,Phase 2
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
15 Keratolytic Agents Phase 4,Phase 2,Not Applicable
16
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
17
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
18
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
19
Tamoxifen Approved Phase 3 10540-29-1 2733526
20
Pitavastatin Approved Phase 3 147511-69-1, 147526-32-7 6366718 5282452
21
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262
22
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Antiparasitic Agents Phase 3,Phase 2,Phase 1
25 Antiprotozoal Agents Phase 3,Phase 2,Phase 1
26 Hematinics Phase 3
27 Antineoplastic Agents, Hormonal Phase 3
28 Aromatase Inhibitors Phase 3
29 Bone Density Conservation Agents Phase 3
30 Estrogen Antagonists Phase 3
31 Estrogen Receptor Modulators Phase 3
32 Estrogens Phase 3
33 Selective Estrogen Receptor Modulators Phase 3
34 Steroid Synthesis Inhibitors Phase 3
35 Anticholesteremic Agents Phase 3
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
37 Hypolipidemic Agents Phase 3
38 Lipid Regulating Agents Phase 3
39 Citrate Nutraceutical Phase 3
40
Gefitinib Approved, Investigational Phase 1, Phase 2,Phase 2 184475-35-2 123631
41
Peginterferon alfa-2a Approved, Investigational Phase 1, Phase 2,Phase 2 198153-51-4 5360545
42
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
43
Cetuximab Approved Phase 2,Not Applicable 205923-56-4 56842117 2333
44
Aminolevulinic acid Approved Phase 2,Not Applicable,Early Phase 1 106-60-5 137
45
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
46
Isotretinoin Approved Phase 2,Not Applicable 4759-48-2 5538 5282379
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
nivolumab Approved Phase 2 946414-94-4
49
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
50
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
2 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
3 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4 Chemopreventive application (Acitretin)
4 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
5 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
6 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
7 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
8 A Study of Vemurafenib in Participants With Metastatic Melanoma Completed NCT01307397 Phase 3 Vemurafenib
9 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
10 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Recruiting NCT02344290 Phase 3 Pitavastatin;Placebo
11 Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer Unknown status NCT02268747 Phase 2 Dacomitinib
12 Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) Unknown status NCT01129154 Phase 2 infusions of Panitumumab
13 Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
14 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
15 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed NCT00126555 Phase 2 Gefitinib
16 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
17 An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) Completed NCT00652080 Phase 1, Phase 2 API 31510
18 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ Completed NCT00329121 Phase 2 PEP005
19 Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Completed NCT00240682 Phase 2 cetuximab
20 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
21 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma Completed NCT00369512 Phase 2 Erlotinib
22 Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis Completed NCT02085395 Phase 2 SR-T100 ® Gel
23 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
24 Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Completed NCT00021294 Phase 2 eflornithine;triamcinolone
25 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002975 Phase 2 aminolevulinic acid
26 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
27 T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Completed NCT00089180 Phase 2 liposomal T4N5 lotion
28 Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Completed NCT01603212 Phase 1, Phase 2 Vemurafenib;IL-2;Interferon Alpha-2b
29 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
30 SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
31 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
32 Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT02760498 Phase 2 REGN2810
33 Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Recruiting NCT03333694 Phase 1, Phase 2 Cutaneous Cream application;Placebo Cutaneous Cream application
34 Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Recruiting NCT03284424 Phase 2
35 Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03565783 Phase 2 REGN2810
36 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Recruiting NCT02964559 Phase 2
37 Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck Recruiting NCT01979211 Phase 2 Cetuximab
38 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
39 Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting NCT03108131 Phase 2 Cobimetinib;Atezolizumab
40 Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion Recruiting NCT03127670 Phase 2 Solanum melongena peel extract 0.05%
41 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
42 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting NCT03082534 Phase 2 Pembrolizumab, Cetuximab
43 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT02218164 Phase 2 Pegylated Interferon alpha-2b;Capecitabine;5-FU
44 Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Active, not recruiting NCT02883556 Phase 2 Pembrolizumab
45 Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin Active, not recruiting NCT01198028 Phase 2 Erlotinib
46 Preventing Squamous Cell Skin Cancer Enrolling by invitation NCT02347813 Phase 2 Pioglitazone
47 A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer Not yet recruiting NCT03327064 Phase 1, Phase 2 UAB30;Placebo
48 Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma Terminated NCT01764607 Phase 2 Sirolimus
49 Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Terminated NCT01823679 Phase 2 Capecitabine
50 Treatment With Nab-paclitaxel in Cutaneous SCC Terminated NCT02076243 Phase 2 nab-paclitaxel

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

41
Skin, Kidney, Lymph Node, Bone, Testes, Lung, Monocytes

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 76)
# Title Authors Year
1
Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway. ( 29663367 )
2018
2
Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. ( 29428730 )
2018
3
IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. ( 29753746 )
2018
4
Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway. ( 29727714 )
2018
5
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. ( 29050985 )
2018
6
Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth inA vitro and inA vivo. ( 28623128 )
2017
7
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. ( 28945253 )
2017
8
CCR5-dependent homing of T regulatory cells to the tumor microenvironment contributes to skin squamous cell carcinoma development. ( 28904130 )
2017
9
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. ( 28507641 )
2017
10
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. ( 28672959 )
2017
11
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line. ( 28176443 )
2017
12
Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. ( 28593886 )
2017
13
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma. ( 28607908 )
2017
14
DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 27471605 )
2016
15
The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. ( 27193637 )
2016
16
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. ( 27714753 )
2016
17
Erratum: Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26845409 )
2016
18
Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. ( 27588122 )
2016
19
Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells. ( 26400287 )
2015
20
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. ( 26391010 )
2015
21
TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. ( 26577853 )
2015
22
Skin squamous cell carcinoma presenting as cellulitis. ( 25635168 )
2015
23
Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma a431 cells. ( 25854367 )
2015
24
Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. ( 26403508 )
2015
25
Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin. ( 26080853 )
2015
26
Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. ( 25966742 )
2015
27
Clinical significance of STAT3 and MAPK phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. ( 26497194 )
2015
28
Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 25915530 )
2015
29
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26168291 )
2015
30
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity. ( 26398820 )
2015
31
Myiasis on squamous cell carcinoma of skin. ( 25387871 )
2014
32
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma. ( 25135431 )
2014
33
Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. ( 25358582 )
2014
34
Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues. ( 25126184 )
2014
35
Advanced skin squamous cell carcinoma: role of radiotherapy. ( 24563891 )
2014
36
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. ( 24917395 )
2014
37
Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. ( 25061226 )
2014
38
The inhibition of resveratrol to human skin squamous cell carcinoma A431 xenografts in nude mice. ( 23428654 )
2013
39
Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. ( 23460078 )
2013
40
Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. ( 22824799 )
2013
41
Expression and function of NET-1 in human skin squamous cell carcinoma. ( 24196235 )
2013
42
HPV type 16-induced skin squamous cell carcinoma located on the groin of immunocompetent patients. ( 24116660 )
2013
43
Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. ( 23188079 )
2012
44
Upregulation of TCTP expression in human skin squamous cell carcinoma increases tumor cell viability through anti-apoptotic action of the protein. ( 22969908 )
2012
45
Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients. ( 22508773 )
2012
46
The incidence of skin squamous cell carcinoma in Osijek-Baranja County--an epidemiological study. ( 22220409 )
2011
47
Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma. ( 21480386 )
2011
48
C/EBPI+ expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPI+ confers susceptibility to UVB-induced skin squamous cell carcinomas. ( 21346772 )
2011
49
Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. ( 21493306 )
2011
50
Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma. ( 20220765 )
2010

Variations for Skin Squamous Cell Carcinoma

Cosmic variations for Skin Squamous Cell Carcinoma:

9
(show top 50) (show all 6898)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM4990875 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 13
2 COSM703213 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 13
3 COSM4990873 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 13
4 COSM4990309 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 13
5 COSM4990310 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 13
6 COSM4991869 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94A 3:147396258-147396258 13
7 COSM4991865 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174F 3:147396018-147396018 13
8 COSM4991861 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292P 3:147391059-147391059 13
9 COSM4991863 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 3:147395971-147395971 13
10 COSM4991867 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 3:147396226-147396226 13
11 COSM4990301 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305E 13:99982979-99982979 13
12 COSM3184673 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 2:43225235-43225235 13
13 COSM3184669 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 2:43225208-43225208 13
14 COSM6963526 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1646C>T p.S549F 16:72958500-72958500 13
15 COSM6974401 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.2933C>T p.A978V 16:72950752-72950752 13
16 COSM6934239 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10688G>A p.R3563K 16:72787588-72787588 13
17 COSM6934240 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.727G>A p.D243N 16:72959419-72959419 13
18 COSM6926616 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10999G>A p.D3667N 16:72787277-72787277 13
19 COSM6944080 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1138C>T p.P380S 16:72959008-72959008 13
20 COSM6926265 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10577G>A p.G3526D 16:72787699-72787699 13
21 COSM6944931 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.7759C>T p.Q2587* 16:72794923-72794923 13
22 COSM4991542 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 22:49883990-49883990 13
23 COSM4993525 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 23:2490119-2490119 13
24 COSM6932261 YES1 skin,NS,carcinoma,squamous cell carcinoma c.373G>A p.E125K 18:748017-748017 13
25 COSM228200 YES1 skin,NS,carcinoma,squamous cell carcinoma c.1499C>T p.S500F 18:724557-724557 13
26 COSM6982918 YES1 skin,NS,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 13
27 COSM6932242 YAP1 skin,NS,carcinoma,squamous cell carcinoma c.938C>T p.S313F 11:102223689-102223689 13
28 COSM4991780 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 2:61488193-61488193 13
29 COSM4829120 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 3:14158444-14158444 13
30 COSM4991848 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 3:14148727-14148727 13
31 COSM4991849 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 3:14148728-14148728 13
32 COSM4991847 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815E 3:14147977-14147977 13
33 COSM4991846 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 3:14147976-14147976 13
34 COSM28974 WT1 skin,NS,carcinoma,squamous cell carcinoma c.935G>A p.R312Q 11:32396367-32396367 13
35 COSM6884834 WT1 skin,NS,carcinoma,squamous cell carcinoma c.964C>T p.P322S 11:32396338-32396338 13
36 COSM4990181 WT1 skin,NS,carcinoma,squamous cell carcinoma c.726C>A p.N242K 11:32417597-32417597 13
37 COSM6939000 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1046-1G>T p.? 11:32392756-32392756 13
38 COSM6917498 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1034G>A p.R345K 11:32396268-32396268 13
39 COSM4990704 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 14:67659823-67659823 13
40 COSM6909326 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.137G>A p.G46E 1:117156882-117156882 13
41 COSM6909324 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.610G>A p.E204K 1:117153205-117153205 13
42 COSM6972902 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.134C>T p.A45V 1:117156885-117156885 13
43 COSM6912242 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.628G>A p.V210I 1:117153187-117153187 13
44 COSM6967157 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.236T>A p.L79* 1:117156783-117156783 13
45 COSM14356 VHL skin,NS,carcinoma,squamous cell carcinoma c.394C>T p.Q132* 3:10146567-10146567 13
46 COSM30228 VHL skin,NS,carcinoma,squamous cell carcinoma c.337C>T p.R113* 3:10142184-10142184 13
47 COSM6937204 VEGFA skin,NS,carcinoma,squamous cell carcinoma c.701C>T p.P234L 6:43777511-43777511 13
48 COSM4991824 UMPS skin,NS,carcinoma,squamous cell carcinoma c.332G>A p.G111E 3:124737589-124737589 13
49 COSM4991823 UMPS skin,NS,carcinoma,squamous cell carcinoma c.331G>A p.G111R 3:124737588-124737588 13
50 COSM4991826 UMPS skin,NS,carcinoma,squamous cell carcinoma c.843G>A p.K281K 3:124738100-124738100 13

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 B2M FBXW7 HRAS KRAS PIK3CA RAC1
2
Show member pathways
13.37 B2M BRAF HRAS KRAS PIK3CA STAT2
3
Show member pathways
13.08 BRAF HRAS KRAS RAC1 TP53
4
Show member pathways
13.03 BRAF HRAS KRAS RAC1 TP53
5
Show member pathways
12.99 HRAS KRAS PIK3CA RAC1 STAT2 TP53
6
Show member pathways
12.96 BRAF HRAS KRAS PIK3CA RAC1 TP53
7
Show member pathways
12.94 HRAS KRAS RAC1 STAT2 TP53
8
Show member pathways
12.93 BRAF HRAS KRAS PIK3CA RAC1
9
Show member pathways
12.93 BRAF HRAS KRAS PIK3CA RAC1
10
Show member pathways
12.92 BRAF HRAS KRAS PIK3CA RAC1
11
Show member pathways
12.89 BRAF HRAS KRAS PIK3CA RAC1
12
Show member pathways
12.88 BRAF HRAS KRAS PIK3CA RAC1 STAT2
13
Show member pathways
12.86 BRAF HRAS KRAS PIK3CA RAC1
14
Show member pathways
12.84 CDKN2A HRAS KRAS PIK3CA TP53
15 12.8 BRAF HRAS KRAS RAC1 TP53
16
Show member pathways
12.78 BRAF CDKN2A HRAS KRAS PIK3CA RAC1
17
Show member pathways
12.76 BRAF HRAS KRAS PIK3CA RAC1
18
Show member pathways
12.76 BRAF CDKN2A HRAS KRAS PIK3CA TP53
19
Show member pathways
12.75 BRAF CDKN2A HRAS KRAS PIK3CA TP53
20
Show member pathways
12.7 BRAF HRAS KRAS PIK3CA RAC1 TP53
21
Show member pathways
12.68 BRAF HRAS KRAS TP53
22 12.65 BRAF HRAS KRAS PIK3CA RAC1
23 12.64 BRAF CDKN2A HRAS KRAS PIK3CA RAC1
24
Show member pathways
12.62 HRAS KRAS PIK3CA RAC1 TP53
25
Show member pathways
12.61 HRAS KRAS PIK3CA RAC1
26
Show member pathways
12.59 BRAF HRAS KRAS PIK3CA
27
Show member pathways
12.54 BRAF HRAS KRAS PIK3CA RAC1
28 12.54 CDKN2A HRAS KRAS PIK3CA TP53
29
Show member pathways
12.54 HRAS KRAS PIK3CA RAC1 STAT2 TP53
30
Show member pathways
12.51 HRAS KRAS PIK3CA RAC1
31
Show member pathways
12.49 BRAF HRAS KRAS PIK3CA RAC1 TP53
32
Show member pathways
12.48 HRAS KRAS PIK3CA RAC1
33
Show member pathways
12.48 HRAS KRAS PIK3CA TP53
34
Show member pathways
12.47 BRAF HRAS KRAS STAT2
35
Show member pathways
12.46 BRAF HRAS KRAS RAC1
36
Show member pathways
12.44 HRAS KRAS PIK3CA RAC1
37
Show member pathways
12.44 HRAS KRAS PIK3CA RAC1
38 12.43 CDKN2A HRAS KRAS PIK3CA TP53
39
Show member pathways
12.42 BRAF HRAS KRAS PIK3CA RAC1 TP53
40
Show member pathways
12.41 BRAF HRAS KRAS PIK3CA RAC1
41
Show member pathways
12.39 HRAS KRAS PIK3CA RAC1
42
Show member pathways
12.39 BRAF HRAS KRAS PIK3CA RAC1
43
Show member pathways
12.37 HRAS KRAS PIK3CA RAC1
44
Show member pathways
12.32 BRAF HRAS KRAS PIK3CA
45
Show member pathways
12.3 BRAF HRAS PIK3CA RAC1
46 12.26 HRAS KRAS PIK3CA RAC1
47
Show member pathways
12.25 HRAS KRAS PIK3CA STAT2
48
Show member pathways
12.25 BRAF HRAS KRAS PIK3CA RAC1 STAT2
49 12.23 BRAF HRAS KRAS RAC1
50 12.21 BRAF HRAS KRAS PIK3CA RAC1 TP53

GO Terms for Skin Squamous Cell Carcinoma

Cellular components related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.36 B2M BRAF CD151 CDKN2A FBXW7 HRAS

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.78 KRAS PIK3CA STAT2 TP53
2 Fc-epsilon receptor signaling pathway GO:0038095 9.62 HRAS KRAS PIK3CA RAC1
3 epidermal growth factor receptor signaling pathway GO:0007173 9.54 HRAS KRAS PIK3CA
4 positive regulation of cellular senescence GO:2000774 9.49 CDKN2A KRAS
5 replicative senescence GO:0090399 9.46 CDKN2A TP53
6 negative regulation of neuron apoptotic process GO:0043524 9.46 BRAF HRAS KRAS PIK3CA
7 regulation of axon regeneration GO:0048679 9.43 BRAF KLF4
8 ERBB2 signaling pathway GO:0038128 9.43 HRAS KRAS PIK3CA
9 response to isolation stress GO:0035900 9.4 HRAS KRAS
10 Ras protein signal transduction GO:0007265 9.26 CDKN2A HRAS KRAS TP53
11 positive regulation of gene expression GO:0010628 9.1 BRAF CDKN2A HRAS KLF4 KRAS TP53

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone deacetylase binding GO:0042826 8.8 KLF4 RAC1 TP53

Sources for Skin Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....